LucyRx, a next-generation pharmacy benefit manager (PBM) known for simplifying and improving access to prescription care, has officially announced the of an Outcomes Accord, which is designed to unite plan sponsors, consultants, brokers, and LucyRx, eventually reaching upon a shared standard for PBM accountability.
According to certain reports, this Outcomes Accord arrives on the scene bearing an ability to define how performance is measured and verified across plans and populations, while simultaneously transcending rebate math and claim discounts. At launch, the stated cohort will be supported by dozens of employers spanning manufacturing, technology, insurance, health care delivery and transportation, leading pharmacy consultants, as well as brokerage firms.
“The Outcomes Accord confronts that reality with results,” said David Blair, CEO of LucyRx. “The clients and consultants who’ve joined as Founders are not just early adopters. They are architects of a model where outcomes are proven, not just promised.”
Talk about Outcomes Accord on a slightly deeper level, it covers, at launch, PMPM cost and yearly trend, actual cost, checked total pharmacy cost per member each month, net of discounts, and rebates.
Next up, there is the point of medication adherence. This involves assessing how consistently members stick to their medicine routines for important health conditions.
Another detail worth a mention is rooted in the prospect of avoided care costs, relating to money saved by preventing unnecessary emergency room visits, hospital stays, or health problems.
Almost like an extension of it, then there are clinical savings coming into play, inclusive of direct health benefits and cost reductions from pharmacy actions.
Joining that would be an aspect committed to member experience. Here, the focus is on how satisfied members are with their access to medicine and the support they receive. Apart from that, LucyRx’s latest development also covers biosimilar adoption, where it essentially lends a thought to safely switching to lower-cost but similar medicines, all for the purpose of improving affordability and value.
“Because if you lose trust, the changes that happen tend to be draconian. They often are legislative, and they’re not as nimble as if industry does it themselves,” said Dr. Mehmet Oz, Administrator of the Centers for Medicare & Medicaid Services.
LucyRx also took this opportunity to unveil its Joining Pathway solution, which makes for a simple request process to help employers and advisors officially sign up and get help with putting the Accord’s standards into action. The company further introduced a group made of different stakeholders who are tasked with regularly reviewing, updating the measurement rules, and ensuring verification is trustworthy.
LucyRx even shed light upon a new metric specification, which packages together a guide that explains how success is measured and verified. It will be made publicly available when approved by the Accord Founders.
Rounding up highlights would be the commitment to publish a yearly performance report, starting in 2026, showcasing verified, easy-to-understand results regarding cost savings and health improvements for participating clients.
“For too long, our industry has focused on good intentions instead of actual results,” said Susan Thomas, Chief Commercial Officer at LucyRx. “The Outcomes Accord changes the way we define and verify performance. It represents a collective dedication to evidence, transparency and a disciplined approach to measuring what truly matters.”
